Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk Factors

Abstract

Chronic obstructive pulmonary disease (COPD) remains a common and important cause of morbidity and mortality both in the United States and globally. The increasing trends of COPD prevalence, morbidity, and mortality seen in the later part of last century have not continued in the United States. COPD prevalence, hospitalizations, and deaths have remained stable or are decreasing over the last decade. This is likely a function of the overall decreasing prevalence of tobacco use over the past 50 years, along with improved therapies for COPD. Future trends in COPD will probably be driven by factors in addition to tobacco use, such as longer survival in the population, other occupational and environmental exposures, and the increasing prevalence of asthma. Globally, factors such as air pollution and chronic respiratory infections, such as tuberculosis, will remain important predictors of future trends.

Keywords

chronic obstructive pulmonary disease - epidemiology - prevalence - morbidity - mortality

• References

• 1 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128 [corrected in Lancet 2013;381(9867):628]
• 2 Vestbo J, Hurd SS, Agustí AG , et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187 (4) 347-365
• 3 Vestbo J, Agusti A, Wouters EF , et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014; 189 (9) 1022-1030
• 4 Anthonisen NR, Connett JE, Kiley JP , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272 (19) 1497-1505
• 5 Bednarek M, Gorecka D, Wielgomas J , et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61 (10) 869-873
• 6 Ulrik CS, Løkke A, Dahl R , et al; TOP study group. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis 2011; 6: 123-127
• 7 Croxton TL, Bailey WC. Long-term oxygen treatment in chronic obstructive pulmonary disease: recommendations for future research: an NHLBI workshop report. Am J Respir Crit Care Med 2006; 174 (4) 373-378
• 8 Celli B, Cross S, Grossman R , et al. Improving the care of COPD patients - suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. Prim Care Respir J 2006; 15 (3) 139-142
• 9 Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005; 72 (5) 471-479
• 10 Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22 (2) 268-273
• 11 Hnizdo E, Glindmeyer HW, Petsonk EL, Enright P, Buist AS. Case definitions for chronic obstructive pulmonary disease. COPD 2006; 3 (2) 95-100
• 12 Lindberg A, Bjerg A, Rönmark E, Larsson LG, Lundbäck B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2006; 100 (2) 264-272 [corrected in Respir Med 2007;101(12):2569]
• 13 Lundbäck B, Lindberg A, Lindström M , et al; Obstructive Lung Disease in Northern Sweden Studies. Not 15 but 50% of smokers develop COPD?—Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97 (2) 115-122
• 14 Buist AS, McBurnie MA, Vollmer WM , et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370 (9589) 741-750
• 15 Menezes AM, Perez-Padilla R, Jardim JR , et al; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366 (9500) 1875-1881
• 16 Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370 (9589) 765-773
• 17 Burney P, Jithoo A, Kato B , et al; Burden of Obstructive Lung Disease (BOLD) Study. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. Thorax 2014; 69 (5) 465-473
• 18 Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117 (2, Suppl): 1S-4S
• 19 Pauwels R. COPD: the scope of the problem in Europe. Chest 2000; 117 (5) (Suppl. 02) 332S-335S
• 20 Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest 2000; 117 (5) (Suppl. 02) 326S-331S
• 21 Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance—United States, 1999-2011. Chest 2013; 144 (1) 284-305
• 22 Vasankari TM, Impivaara O, Heliövaara M , et al. No increase in the prevalence of COPD in two decades. Eur Respir J 2010; 36 (4) 766-773
• 23 Soriano JB, Ancochea J, Miravitlles M , et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J 2010; 36 (4) 758-765
• 24 Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 2010; 170 (6) 560-565
• 25 Kojima S, Sakakibara H, Motani S , et al. Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population. J Epidemiol 2007; 17 (2) 54-60
• 26 de Marco R, Accordini S, Cerveri I , et al; European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59 (2) 120-125
• 27 Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ 2002; 51 (6) 1-16
• 28 Tan WC, Seale P, Ip M , et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology 2009; 14 (1) 90-97
• 29 Chronic Obstructive Pulmonary Disease. 2014. Available at: http://www.cdc.gov/copd/data.htm . Accessed September 26, 2014
• 30 Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults—United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61 (46) 938-943
• 31 Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest 2013; 143 (5) 1395-1406
• 32 Chapman KR, Mannino DM, Soriano JB , et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27 (1) 188-207
• 33 Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest 2015; 147 (1) 31-45
• 34 Rabe KF, Hurd S, Anzueto A , et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176 (6) 532-555
• 35 Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ 2001; 79 (10) 971-979
• 36 Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD 2006; 3 (4) 211-218
• 37 Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128 (4) 2005-2011
• 38 Anthonisen NR, Connett JE, Enright PL, Manfreda J ; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166 (3) 333-339
• 39 Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22 (5) 809-814
• 40 Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163 (12) 1475-1480
• 41 Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32 (4) 962-969
• 42 Jørgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007; 101 (1) 177-185
• 43 Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29 (5) 923-929
• 44 Hill K, Geist R, Goldstein RS, Lacasse Y. Anxiety and depression in end-stage COPD. Eur Respir J 2008; 31 (3) 667-677
• 45 Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 2005; 26 (4) 703-719
• 46 Celli BR, Cote CG, Marin JM , et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (10) 1005-1012
• 47 Crisafulli E, Costi S, Luppi F , et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63 (6) 487-492
• 48 van Manen JG, Bindels PJ, Dekker FW , et al. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 2003; 56 (12) 1177-1184
• 49 Antonelli Incalzi R, Fuso L, De Rosa M , et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10 (12) 2794-2800
• 50 Terzano C, Conti V, Di Stefano F , et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010; 188 (4) 321-329
• 51 van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schadé E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54 (3) 287-293
• 52 Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7 (5) 375-382
• 53 McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA ; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62 (5) 411-415
• 54 Camp PG, Chaudhry M, Platt H , et al. The sex factor: epidemiology and management of chronic obstructive pulmonary disease in British Columbia. Can Respir J 2008; 15 (8) 417-422
• 55 Nie JX, Wang L, Upshur RE. Mortality of elderly patients in Ontario after hospital admission for chronic obstructive pulmonary disease. Can Respir J 2007; 14 (8) 485-489
• 56 Lindberg A, Lundbäck B. The Obstructive Lung Disease in Northern Sweden Chronic Obstructive Pulmonary Disease Study: design, the first year participation and mortality. Clin Respir J 2008; 2 (Suppl. 01) 64-71
• 57 Janssen F, Kunst AE ; Netherlands Epidemiology and Demography Compression of Morbidity research group. Cohort patterns in mortality trends among the elderly in seven European countries, 1950-99. Int J Epidemiol 2005; 34 (5) 1149-1159
• 58 Wilson DH, Tucker G, Frith P, Appleton S, Ruffin RE, Adams RJ. Trends in hospital admissions and mortality from asthma and chronic obstructive pulmonary disease in Australia, 1993-2003. Med J Aust 2007; 186 (8) 408-411
• 59 Janssen F, Nusselder WJ, Looman CW, Mackenbach JP, Kunst AE. Stagnation in mortality decline among elders in the Netherlands. Gerontologist 2003; 43 (5) 722-734
• 60 Berend N. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1-antitrypsin deficiency in Australia. Respirology 2001; 6 (Suppl): S21-S25
• 61 Puhan MA, Garcia-Aymerich J, Frey M , et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374 (9691) 704-711
• 62 Jones RC, Donaldson GC, Chavannes NH , et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180 (12) 1189-1195
• 63 Divo M, Cote C, de Torres JP , et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186 (2) 155-161
• 64 Lange P, Marott JL, Vestbo J , et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186 (10) 975-981
• 65 WHO. WHO Report on the Global Tobacco Epidemic: 2011. Geneva: World Health Organization; 2011
• 66 Giovino GA, Mirza SA, Samet JM , et al; GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 2012; 380 (9842) 668-679
• 67 Foreman MG, Zhang L, Murphy J , et al; COPDGene Investigators. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011; 184 (4) 414-420
• 68 Agustí A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component?. Thorax 2003; 58 (10) 832-834
• 69 Marsh S, Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Smoking and COPD: What really are the risks?. Eur Respir J 2006; 28 (4) 883-884
• 70 Lopez AD, Begg S, Bos E. Demographic and Epidemiological Characteristics of Major Regions, 1990–2001. In: Lopez AD, Mathers CD, Ezzati M, , et al., editors. Global Burden of Disease and Risk Factors. Washington (DC): World Bank; 2006. . Chapter 2. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11807/
• 71 Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ ; Comparative Risk Assessment Collaborating Group. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med 2004; 1 (1) e27
• 72 Gilliland FD, Li YF, Dubeau L , et al. Effects of glutathione S-transferase M1, maternal smoking during pregnancy, and environmental tobacco smoke on asthma and wheezing in children. Am J Respir Crit Care Med 2002; 166 (4) 457-463
• 73 Thun MJ, Carter BD, Feskanich D , et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368 (4) 351-364
• 74 Taylor Jr DH, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92 (6) 990-996
• 75 Najafzadeh M, Marra CA, Lynd LD , et al. Future impact of various interventions on the burden of COPD in Canada: a dynamic population model. PLoS ONE 2012; 7 (10) e46746
• 76 Rutgers SR, Postma DS, ten Hacken NH , et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55 (1) 12-18
• 77 Xu X, Dockery DW, Ware JH, Speizer FE, Ferris Jr BG. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146 (5, Pt 1) 1345-1348
• 78 Simmons MS, Connett JE, Nides MA , et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J 2005; 25 (6) 1011-1017
• 79 Sherrill DL, Holberg CJ, Enright PL, Lebowitz MD, Burrows B. Longitudinal analysis of the effects of smoking onset and cessation on pulmonary function. Am J Respir Crit Care Med 1994; 149 (3, Pt 1) 591-597
• 80 Scanlon PD, Connett JE, Waller LA , et al; Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161 (2, Pt 1) 381-390
• 81 Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE ; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142 (4) 233-239
• 82 Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med 2005; 118 (12) 1364-1372
• 83 Lamprecht B, Schirnhofer L, Kaiser B, Buist S, Studnicka M. Non-reversible airway obstruction in never smokers: results from the Austrian BOLD study. Respir Med 2008; 102 (12) 1833-1838
• 84 Behrendt CE. Mild and moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128 (3) 1239-1244
• 85 Bridevaux PO, Probst-Hensch NM, Schindler C , et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J 2010; 36 (6) 1259-1269
• 86 Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374 (9691) 733-743
• 87 Lamprecht B, McBurnie MA, Vollmer WM , et al; BOLD Collaborative Research Group. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139 (4) 752-763
• 88 Zhou Y, Wang C, Yao W , et al. COPD in Chinese nonsmokers. Eur Respir J 2009; 33 (3) 509-518
• 89 Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126 (1) 59-65
• 90 Xu X, Rijcken B, Schouten JP, Weiss ST. Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 1997; 350 (9089) 1431-1434
• 91 American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (5, Pt 2) S77-S121
• 92 Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58 (4) 322-327
• 93 Hudon C, Turcotte H, Laviolette M, Carrier G, Boulet LP. Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Annals of Allergy, Asthma Immunology. 1997; 78 (2) 195-202
• 94 Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999; 103 (4) 539-547
• 95 Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999; 14 (4) 892-896
• 96 Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339 (17) 1194-1200
• 97 Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70 (3) 171-179
• 98 Sherrill D, Guerra S, Bobadilla A, Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur Respir J 2003; 21 (1) 95-100
• 99 Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150 (3) 629-634
• 100 Cassino C, Berger KI, Goldring RM , et al. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med 2000; 162 (4, Pt 1) 1423-1428
• 101 Connolly CK, Chan NS, Prescott RJ. The relationship between age and duration of asthma and the presence of persistent obstruction in asthma. Postgrad Med J 1988; 64 (752) 422-425
• 102 Balmes J, Becklake M, Blanc P , et al; Environmental and Occupational Health Assembly, American Thoracic Society. American Thoracic Society Statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003; 167 (5) 787-797
• 103 Trupin L, Earnest G, San Pedro M , et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22 (3) 462-469
• 104 Bergdahl IA, Torén K, Eriksson K , et al. Increased mortality in COPD among construction workers exposed to inorganic dust. Eur Respir J 2004; 23 (3) 402-406
• 105 Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156 (8) 738-746
• 106 Harber P, Tashkin DP, Simmons M, Crawford L, Hnizdo E, Connett J ; Lung Health Study Group. Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (10) 994-1000
• 107 Blanc PD, Iribarren C, Trupin L , et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009; 64 (1) 6-12
• 108 Blanc PD, Menezes AM, Plana E , et al. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J 2009; 33 (2) 298-304
• 109 Bruce N, Perez-Padilla R, Albalak R. Indoor air pollution in developing countries: a major environmental and public health challenge. Bull World Health Organ 2000; 78 (9) 1078-1092
• 110 Kurmi OP, Semple S, Simkhada P, Smith WC, Ayres JG. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010; 65 (3) 221-228
• 111 Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramírez-Sarmiento A, Antó JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J 2006; 27 (3) 542-546
• 112 Osman LM, Douglas JG, Garden C , et al. Indoor air quality in homes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176 (5) 465-472
• 113 Hunt A, Abraham JL, Judson B, Berry CL. Toxicologic and epidemiologic clues from the characterization of the 1952 London smog fine particulate matter in archival autopsy lung tissues. Environ Health Perspect 2003; 111 (9) 1209-1214
• 114 Sunyer J. Urban air pollution and chronic obstructive pulmonary disease: a review. Eur Respir J 2001; 17 (5) 1024-1033
• 115 Holguin F, Flores S, Ross Z , et al. Traffic-related exposures, airway function, inflammation, and respiratory symptoms in children. Am J Respir Crit Care Med 2007; 176 (12) 1236-1242
• 116 Nicolai T, Carr D, Weiland SK , et al. Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children. Eur Respir J 2003; 21 (6) 956-963
• 117 Janssen NA, Brunekreef B, van Vliet P , et al. The relationship between air pollution from heavy traffic and allergic sensitization, bronchial hyperresponsiveness, and respiratory symptoms in Dutch schoolchildren. Environ Health Perspect 2003; 111 (12) 1512-1518
• 118 Hogervorst JG, de Kok TM, Briedé JJ, Wesseling G, Kleinjans JC, van Schayck CP. Relationship between radical generation by urban ambient particulate matter and pulmonary function of school children. J Toxicol Environ Health A 2006; 69 (3-4) 245-262
• 119 Tager IB, Balmes J, Lurmann F, Ngo L, Alcorn S, Künzli N. Chronic exposure to ambient ozone and lung function in young adults. Epidemiology 2005; 16 (6) 751-759
• 120 Kulkarni N, Pierse N, Rushton L, Grigg J. Carbon in airway macrophages and lung function in children. N Engl J Med 2006; 355 (1) 21-30
• 121 Frye C, Hoelscher B, Cyrys J, Wjst M, Wichmann HE, Heinrich J. Association of lung function with declining ambient air pollution. Environ Health Perspect 2003; 111 (3) 383-387
• 122 Sugiri D, Ranft U, Schikowski T, Krämer U. The influence of large-scale airborne particle decline and traffic-related exposure on children's lung function. Environ Health Perspect 2006; 114 (2) 282-288
• 123 Avol EL, Gauderman WJ, Tan SM, London SJ, Peters JM. Respiratory effects of relocating to areas of differing air pollution levels. Am J Respir Crit Care Med 2001; 164 (11) 2067-2072
• 124 Schikowski T, Sugiri D, Ranft U , et al. Long-term air pollution exposure and living close to busy roads are associated with COPD in women. Respir Res 2005; 6: 152
• 125 Ackermann-Liebrich U, Leuenberger P, Schwartz J , et al; Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. Lung function and long term exposure to air pollutants in Switzerland. Am J Respir Crit Care Med 1997; 155 (1) 122-129
• 126 Forbes LJ, Kapetanakis V, Rudnicka AR , et al. Chronic exposure to outdoor air pollution and lung function in adults. Thorax 2009; 64 (8) 657-663
• 127 Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 1991; 143 (6) 1224-1230
• 128 Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res 2006; 7: 52
• 129 Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Sex differences in lung vulnerability to tobacco smoking. Eur Respir J 2003; 21 (6) 1017-1023
• 130 Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10 (4) 822-827
• 131 Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994; 7 (6) 1056-1061
• 132 Sørheim IC, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men?. Thorax 2010; 65 (6) 480-485
• 133 Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001; 119 (6) 1691-1695
• 134 Miravitlles M, de la Roza C, Naberan K , et al. [Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care]. Arch Bronconeumol 2006; 42 (1) 3-8
• 135 Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993; 104 (1) 254-258
• 136 Watson L, Vestbo J, Postma DS , et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med 2004; 98 (12) 1207-1213
• 137 Døssing M, Khan J, al-Rabiah F. Risk factors for chronic obstructive lung disease in Saudi Arabia. Respir Med 1994; 88 (7) 519-522
• 138 Dennis RJ, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996; 109 (1) 115-119
• 139 Pérez-Padilla R, Regalado J, Vedal S , et al. Exposure to biomass smoke and chronic airway disease in Mexican women. A case-control study. Am J Respir Crit Care Med 1996; 154 (3, Pt 1) 701-706
• 140 Ekici A, Ekici M, Kurtipek E , et al. Obstructive airway diseases in women exposed to biomass smoke. Environ Res 2005; 99 (1) 93-98
• 141 Peabody JW, Riddell TJ, Smith KR , et al. Indoor air pollution in rural China: cooking fuels, stoves, and health status. Arch Environ Occup Health 2005; 60 (2) 86-95
• 142 Liu S, Zhou Y, Wang X , et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007; 62 (10) 889-897
• 143 Romieu I, Riojas-Rodríguez H, Marrón-Mares AT, Schilmann A, Perez-Padilla R, Masera O. Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women. Am J Respir Crit Care Med 2009; 180 (7) 649-656
• 144 Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365 (9478) 2225-2236
• 145 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168 (7) 818-900
• 146 Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax 1994; 49 (7) 695-698
• 147 Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). Thorax 1997; 52 (3) 244-248
• 148 Ingebrigtsen T, Thomsen SF, Vestbo J , et al. Genetic influences on chronic obstructive pulmonary disease—a twin study. Respir Med 2010; 104 (12) 1890-1895
• 149 Lee JH, Cho MH, Hersh CP , et al; COPDGene and ECLIPSE Investigators. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respir Res 2014; 15: 113
• 150 Hooper R, Burney P, Vollmer WM , et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39 (6) 1343-1353
• 151 Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration 2013; 86 (1) 76-85
• 152 Andréjak C, Nielsen R, Thomsen VO, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68 (3) 256-262
• 153 Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013; 143 (4) 1018-1024
• 154 Lee CH, Lee MC, Lin HH , et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS ONE 2012; 7 (5) e37978
• 155 Carraro S, Filippone M, Da Dalt L , et al. Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. Early Hum Dev 2013; 89 (Suppl. 03) S3-S5
• 156 Vollsæter M, Røksund OD, Eide GE, Markestad T, Halvorsen T. Lung function after preterm birth: development from mid-childhood to adulthood. Thorax 2013; 68 (8) 767-776
• 157 Filippone M, Carraro S, Baraldi E. From BPD to COPD? The hypothesis is intriguing but we lack lung pathology data in humans. Eur Respir J 2010; 35 (6) 1419-1420 , author reply 1420
• 158 Madeddu G, Fois AG, Calia GM , et al. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era?. Infection 2013; 41 (2) 347-353
• 159 Raynaud C, Roche N, Chouaid C. Interactions between HIV infection and chronic obstructive pulmonary disease: clinical and epidemiological aspects. Respir Res 2011; 12: 117
• 160 Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis 2014; 9: 229-238
• 161 Sethi S. Chronic obstructive pulmonary disease and infection. Disruption of the microbiome?. Ann Am Thorac Soc 2014; 11 (Suppl. 01) S43-S47
• 162 Garrett BE, Dube SR, Trosclair A, Caraballo RS, Pechacek TF ; Centers for Disease Control and Prevention (CDC). Cigarette smoking—United States, 1965-2008. MMWR Surveill Summ 2011; 60 (Suppl): 109-113